Soligenix Inc.

SNGX Healthcare Biotechnology

Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023. In the quarter to June 2026, EPS grew 85.4% and free cash flow grew 37.8%, each against the same quarter a year earlier.

0.35 0.01 −2.78%
Market cap
$7.7M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
n/a
Altman Z
−38.90
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(241.65%) (326.88%) (235.50%) (165.10%)

+8 more TTM periods

ROA
(125.95%) (149.35%) (121.75%) (102.63%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(157.37%) (370.87%) (214.80%) (149.62%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(0.61) (1.06) (1.98) (2.25)
Free Cash Flow
(9.74) (10.78) (10.27) (9.76)
Capital Expenditures
— — (0.01) 0.00
Other line items
Cash ROIC
(59.20%) (118.18%) (77.66%) (53.84%)
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Operating CF/Net income
0.95 0.98 0.93 0.87
Depreciation/Fixed assets
0.62 0.48 0.36 0.41
Capex/Depreciation
0.00 0.00 (1.84) (1.22)
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.61) (1.06) (1.98) (2.25)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
— — 0.00 0.00

Fold the line items

Columns are period end dates